Most people on semaglutide (the active ingredient in Ozempic) lose between 10% and 15% of their body weight over the course of a year or more. For someone starting at 250 pounds, that translates to roughly 25 to 38 pounds. But the actual number depends on your dose, how long you stay on it, and whether you pair it with diet and exercise changes.
What Clinical Trials Show
The best long-term data comes from the STEP clinical trial program, which tested semaglutide at a 2.4 mg weekly dose (the dose used in Wegovy, the version FDA-approved specifically for weight loss). In the STEP 5 trial, participants lost an average of 15.2% of their body weight over two years, compared to just 2.6% in the placebo group. Shorter trials showed similar results: STEP 1 found 12.4% more weight loss than placebo at 68 weeks, and STEP 3 showed 10.3% more.
Ozempic itself is FDA-approved for type 2 diabetes, not weight management, and tops out at a lower dose (up to 2 mg weekly versus Wegovy’s 2.4 mg). That means weight loss on Ozempic specifically may be somewhat lower than the STEP trial numbers, though many doctors prescribe it off-label for weight loss at the highest available dose.
A Realistic Timeline
Weight loss on semaglutide is gradual, not dramatic in the first few weeks. Clinical trial data shows a fairly predictable pattern:
- Month 1: About 2% of body weight, so roughly 4 to 5 pounds for someone starting at 220 pounds.
- Months 2 to 3: Weight loss picks up to around 4 to 6% total. One study of adults without diabetes found an average 6.3% loss after three months.
- Month 6: Most people reach a 6 to 10% reduction in body weight.
- Month 12 and beyond: Weight loss continues gradually, with most people reaching their maximum results around 60 weeks (roughly 14 months) into treatment.
The slow start is partly by design. Ozempic is prescribed at a low starting dose and increased every four weeks to reduce nausea and other gut-related side effects. You won’t be on the full maintenance dose until at least month two or three.
Clinical Trials vs. Real Life
Trial participants have regular check-ins, dietitians, and strong motivation to stick with treatment. Real-world results are more modest. A large Cleveland Clinic study compared the two and found that patients who stayed on semaglutide at a high maintenance dose lost an average of 13.7% of their body weight after one year. That’s close to trial numbers. But the averages drop quickly when you factor in the many people who reduce their dose or stop early. Patients who discontinued treatment lost only 3.6% to 6.8% on average, depending on how long they lasted.
The takeaway: consistency matters more than almost anything else. The people who stay on the medication at a therapeutic dose get results that closely mirror the clinical trials. Those who stop early, whether due to side effects, cost, or supply issues, see far less benefit.
How Semaglutide Causes Weight Loss
Semaglutide mimics a hormone your gut naturally produces after eating called GLP-1. This hormone signals your brain that you’re full. The medication amplifies that signal, making you feel satisfied with less food. It also slows the rate at which your stomach empties, so meals keep you feeling full longer.
Beyond appetite suppression, semaglutide appears to shift food preferences. People on the medication report less craving for fatty, calorie-dense foods. Combined, these effects lead to a significant drop in daily calorie intake without the constant hunger that derails most diets.
What Happens When You Stop
This is the part most people don’t hear about upfront. In the STEP 1 trial extension, participants who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost within the following year. Those who had lost an average of 17% of their body weight ended up at a net loss of only 5.6% one year after stopping.
This doesn’t mean the medication “failed.” Obesity is a chronic condition driven by hormonal and metabolic signals that don’t reset permanently. When the medication is removed, appetite and hunger patterns return to baseline. This is why most obesity specialists consider semaglutide a long-term treatment rather than a short course.
How It Compares to Tirzepatide
Tirzepatide (sold as Zepbound for weight loss and Mounjaro for diabetes) targets two gut hormones instead of one and produces more weight loss on average. In clinical trials, people without diabetes on the highest dose of tirzepatide lost up to 21% of their body weight, with an average of 18% at the top dose. In real-world settings, the Cleveland Clinic study found 18% body weight loss for patients on high-dose tirzepatide who stayed on treatment, compared to 13.7% for semaglutide.
Both medications are effective, but if maximizing weight loss is the primary goal, tirzepatide has a clear edge in the data available so far.
Side Effects That Affect Results
Nausea, vomiting, diarrhea, and constipation are the most common side effects, and they’re the main reason people reduce their dose or quit. The good news from pooled trial data: 99.5% of gut-related side effects were classified as non-serious, and 98% were mild to moderate. Most people can manage them, especially during the gradual dose escalation period. Older adults tend to have higher rates of discontinuation due to side effects.
If side effects force you to stay on a lower dose, your weight loss will likely be lower than the headline trial numbers. But even partial doses produce meaningful results compared to diet and exercise alone.
The Weight Loss Plateau
Nearly everyone on semaglutide hits a plateau where weight loss stalls. Based on clinical data, this typically happens around 60 weeks into treatment. At that point, your body has adjusted to a lower calorie intake and a lower weight, and the rate of loss flattens out. This isn’t a failure of the drug. It’s the expected endpoint. The goal after the plateau shifts from losing weight to maintaining the loss, which semaglutide continues to support as long as you stay on it.